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We report on a familial Mediterranean fever (FMF) patient homozygous for p.M694V in the MEFV gene who
developed chronic myelomonocytic leukemia (CMML) leading to an uncontrolled and fatal inflammatory syndrome.
Plasma levels of IL-6 and IL-18 were found to be very high, as compared to healthy controls and CMML-free FMF
patients.
Our study unveils the interplay between two different disorders involving the same target cells, suggesting that in
myelodysplasia with inflammatory manifestations, mutations in genes causing autoinflammatory syndromes, like
MEFV, can be present and thus could be sought. Early chemotherapy with interleukin inhibitors could be proposed
in such unusual situations.
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Letters to the Editor:
Familial Mediterranean fever (FMF) is an autosomal
recessive autoinflammatory disorder caused by muta-
tions in the MEFV gene, mainly p.M694V in exon 10
[1, 2]. It is the commonest hereditary fever syndrome
with recurrent episodes of fever accompanied by abdom-
inal, chest and joint pain. MEFV encodes pyrin, a pro-
tein expressed in neutrophils and monocytes [3] and is
involved in the regulation of inflammation. Daily and
life-long colchicine administration can prevent both
attacks and occurrence of inflammatory amyloidosis.
Ex-vivo studies performed with monocytes from FMF
patients have demonstrated the importance of increased
secretion of the potent pyrogenic cytokine interleukin
(IL)-1β. Subsequently, IL-1 inhibitors have been pro-
posed as alternative or supplementary treatment in* Correspondence: serge.amselem@inserm.fr; ohermine@gmail.com; sonia.
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creativecommons.org/publicdomain/zero/1.0/colchicine-resistant patients or in those presenting ad-
verse events [4]. In addition, blocking the IL-1 pathway
is safer, in terms of infectious risk, in comparison with
other biological treatments [5, 6].
Chronic myelomonocytic leukemia (CMML) is a
clonal hematopoietic stem cell disorder classified as a mye-
lodysplastic/myeloproliferative neoplasm [7, 8]. CMML is
characterized by absolute monocytosis (>1 × 109/L) in per-
ipheral blood persisting for at least 3 months [8]. The me-
dian age of CMML diagnosis is 70 years [7] and current
treatment includes hydroxyurea and/or 5-azacitidine [8].
We report a case of an 84-year-old man who had typ-
ical FMF since his childhood. The diagnosis of FMF was
confirmed by identification in the MEFV gene of the
M694V mutation in the homozygous state. Lifelong col-
chicine therapy (1 mg/day) for 40 years abolished febrile
crises. No other medical problem was reported. At the
age of 83 (t = 0), he started complaining of general weak-
ness and a blood test showed profound macrocytic anemia,
with no other cytopenia (Hb = 7.2 g/dL; MCV= 104 fL;
leukocytes 7.6 × 109/L; platelets 228 × 109/L). Additional la-
boratory tests showed no signs of hemolysis, inflammatory
disease, hypothyroidism or deficiency in vitamin B12 or
B9. Thus, a bone marrow smear was performed andicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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I&II) and with a normal karyotype. He received itera-
tive red blood cell transfusions and vitamin D.
Six months later (t = 6), he presented with asthenia,
fever and biological inflammatory syndrome although he
took the same dose of colchicine. Serum amyloid A (SAA)
as well as C-reactive protein (CRP) levels were elevated
(226 and 20 mg/L respectively), and Hb was low (6.9 g/dL).
Neither infection nor profound neoplasia was detected. He
had no proteinuria, and salivary gland biopsy revealed no
amyloidosis. Colchicine was increased to 1.5 mg per day,
but because of occurrence of diarrhea –a well-known
side effect of colchicine therapy–, the dose was finally
maintained 1mg/day. During the following 3 months,
his general status got worse: he lost 10 kg, fever and in-
flammatory syndrome persisted and required weekly
red blood cell transfusions because of severe anemia
(Hb = 5.5 g/dL). His condition suddenly deteriorated,
with elevated fever and fatigue. Further investigations
showed a progressive increase in monocyte count above
1 × 109/L with persistent anemia (Hb = 6.8 g/dL) and
severe inflammatory syndrome (SAA = 327 mg/L; CRP
80 mg/L; Fig. 1b). A new bone marrow smear confirmed
CMML (Fig. 1a, III&IV). He died 6 months later fromc
a
I
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Fig. 1 Morphological features of CMML in patient #9 and cytokine profiles
CMML and FMF (see Additional file 1: Table S1) (I) showing dysgranulopoie
arrow) at t = 0; (II) dysplastic binucleate erythroblasts at the stage of myelo
(indicated with an arrow) at t = 6; (IV) appearance of a monocytosis (solid a
at t = 6. b Blood monocyte counts and serum CRP levels at the indicated t
about symptoms worsening. The solid black arrow indicates the time of CM
drawn for cytokine measurements. c IL-6 levels in plasma samples from pa
ELISA. d IL-18 levels in plasma samples from patient #9, FMF patients and apneumonia in the context of persistent profound anemia
(Hb = 6.5 g/dL) and inflammation.
FMF patients have been shown to display high plasma
levels of proinflammatory cytokines [9]. Their mono-
cytes are spontaneously activated and secrete high levels
of IL-1β [10]. Cytokines implicated in the pathophysi-
ology of FMF such as IL-1β, IL-18 and IL-6 are import-
ant for the regulation of immune and inflammatory
responses. These cytokines are also involved in the
pathophysiology of inflammatory anemia due to erythro-
poiesis blockade [11, 12]. It is therefore tempting to
speculate that the transformation of refractory anemia
into CMML, which resulted in an increased number of
circulating monocytes in our FMF patient, could be
responsible for the persistent inflammatory syndrome. In
keeping with this hypothesis, the progressive monocyto-
sis was accompanied by a progressive elevation of CRP
levels (Fig. 1b) and persistence of refractory anemia.
We measured the plasma levels of IL-1β, IL-18 and
IL-6 in the patient [see Patients and Methods in Additional
file 1], 10 months (t = 10) after t = 0, and compared
them with cytokine levels from FMF patients carrying
unambiguous MEFV mutations (n = 8) [see Table S1 for
genotype, inflammatory and clinical status of the FMFb
d
in patients and controls. a Bone marrow smears from patient #9 with
sis (hypogranular cytoplasm and Döhle bodies indicated with the
dysplastic syndrome (t = 0); (III) persistence of myeloid dysplasia
rrow) with excess of blasts (dashed arrow) when progression to CMML
ime points in patient #9. t = 0 is first time the patient complained
ML diagnosis and the dashed arrow indicates when plasma was
tient #9, FMF patients and apparently healthy controls, as quantified by
pparently healthy controls, as quantified by ELISA
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cytokine known to induce acute phase proteins, was not
detected in the controls’ plasma but was present at a con-
centration of 64 pg/mL in the CMML patient and also
easily detectable in 4 other FMF patients (3–177 pg/mL), of
whom 3 were under colchicine therapy (Fig. 1c). IL-1β is
produced by monocytes and tissue macrophages as a pre-
cursor, which is then processed to its active form by the
inflammasome, an intracellular multiprotein complex [13].
IL-1β is mainly detected in supernatants of monocyte cul-
ture after stimulation with Toll-Like receptor agonists like
lipopolysaccharide [10]. Although ex-vivo studies demon-
strated a major role of IL-1β in the pathogenesis of FMF,
serum levels have been reported normal or even decreased
in FMF patients [14]. Accordingly, IL-1β was not detected
in the patient’s plasma, in controls, and in 6 out of the 8
FMF patients (data not shown). IL-18, which is also
secreted by monocytes and regulated by inflammasome,
was found at much higher levels in the patient’s plasma
(7647 pg/mL) than in other patients (187–4527 pg/mL) or
controls (172–246 pg/mL) (Fig. 1d). As these cytokines
are known to be involved in chronic inflammation in FMF
[9, 10], their presence could readily explain the un-
controlled inflammation seen in the patient.
From a more general viewpoint, our study unveils the
interplay between two different disorders involving the same
target cells. More specifically, it suggests that in myelodyspla-
sia with inflammatory manifestations [15, 16], mutations in
genes causing autoinflammatory syndromes, such as those
found in MEFV, can be present and thus could be sought
[17]. In this context it is interesting to note that an allogenic
bone marrow transplantation on a young patient who had
congenital dyserythropoietic anemia and FMF was once re-
ported to significantly improve/treat the FMF symptoms [18]
due to the hematopoietic involvement of the two disorders.
Our data suggest that among elderly FMF patients, with
CMML, a severe inflammatory syndrome may appear and
has to be treated. CMML diagnosis should be confirmed by
bone marrow aspiration; and cytotoxic chemotherapy and/
or a demethylating agent should be considered in order to
reduce monocytosis. This is even more important, as
monocytosis is a key factor in the pathogenesis of FMF and
the subsequent production of proinflammatory cytokines.
In these rare cases of FMF or other autoinflammatory dis-
eases combined with CMML, interleukin inhibitors (against
IL-1, IL-6 or IL-18) alone or associated with a demethylat-
ing agent could represent a valuable therapeutic strategy to
decrease a potentially fatal inflammatory syndrome.Additional file
Additional file 1: Patients and Methods. Table S1. Genotype,
inflammatory and clinical status of the FMF patients.Abbreviations
FMF: Familial Mediterranean fever; CMML: Chronic myelomonocytic leukemia;
CRP: C reactive protein; IL: Interleukin; SAA: Serum amyloid A.
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